2018-002367-26: Parallel group, blinded, multi-centre study of mifepristone in patients with endometriosis |
|
|
| Ongoing | 3 | 490 | Europe | Mifepristone 2.5 mg tablets, Mifepristone 5 mg tablets, Mifepristone 2.5 mg tablets, Mifepristone 5 mg tablets, Tablet | Litaphar Laboratorios, Litaphar Laboratorios | endometriosis in reproductive-age, endometriosis in reproductive-age, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | | | | |
2020-004302-63: A multi-centre, open-label, single-arm study assessing the safety and efficacy of 5 mg of mifepristone for the treatment of endometriosis in reproductive-age women during two treatment cycles of 24 weeks each |
|
|
| Ongoing | 3 | 300 | Europe | Mifepristone 5 mg, Mifepristone 5 mg, Tablet | Litaphar Laboratorios S.L., Litaphar Laboratorios S.L. | endometriosis in reproductive-age, endometriosis in reproductive-age, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | | | | |
